ORCHID PHARMA LTD Q2 RESULTS
RVNL among India Inc's unlucky 13 with over 25% drop in both sales, profit in Q1
To maintain a premium valuation, a stock must demonstrate strong earnings growth and a positive future outlook. However, the June quarter results revealed that several prominent companies, including popular retail multibaggers, fell short in terms of earnings. ETMarkets reviewed companies with an m-cap of at least Rs 5,000 crore and identified 13 entities that reported at least a 25% YoY decline in sales and profit.
Q1 results today: IRFC, Vodafone Idea among 528 companies to announce earnings on Monday
As the first quarter earnings season nears its end, 528 companies are set to release their results on Monday. Key reports include IRFC, Vodafone Idea, and NMDC. Vodafone Idea is expected to report flat revenue and losses between Rs 7,489-8,100 crore. EBITDA is forecasted to see a slight year-on-year rise despite challenges.
LIC stock portfolio surges to Rs 15 lakh crore, 95 stocks sold in Q1
Life Insurance Corporation of India's equity portfolio has nearly doubled in three years to Rs 15.72 lakh crore. In the June quarter, LIC reduced stakes in 95 stocks, including Bank of Maharashtra, while increasing investments in firms such as Infosys and TCS. Fund managers advise rotating into value sectors for optimal returns.
Alembic Pharma Q1 Results: Net profit rises 12% YoY to Rs 135 crore
Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 14% YoY to Rs 239 crore, while the EBITDA margins contracted 540 basis points on y-o-y basis to 15.3%
Lupin shares surge 6%, hit 52-week high post robust Q1 result
Lupin Share Price: Lupin's shares jumped 6% to a 52-week high after the company announced a 77.2% increase in net profit for the June quarter of FY25. The firm's net profit was Rs 801.3 crore, and revenue rose 16.3% to Rs 5,600.3 crore. Nomura maintained a 'Buy' rating, forecasting continued growth.
Q1 results today: Vedanta among 132 companies to announce earnings on Tuesday
During the first quarter earnings season, 132 companies, including PFC and Tata Power, were scheduled to announce their financial results. Vedanta's net profit was expected to range between Rs 2,197-3,060 crore, with revenue estimates between Rs 35,440-38,674 crore for June 2024. Different brokerages provided varying growth predictions.
- Go To Page 1
Divi's Laboratories Q1 Results: Cons PAT jumps 21% YoY to Rs 430 crore, misses estimates
Divi's Laboratories reported a consolidated net profit of Rs 430 crore for the quarter ended June 30, 2024, which was up by 21% over Rs 356 crore reported by the company in the year ago period. It was lower than Street's estimates of Rs 448 crore.
Sun Pharma Q1 Results: Net profit rises 40% YoY to Rs 2,836 crore, beats estimates
Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales.
Be a bit cautious in auto stocks and do not chase the particular rally in Maruti: Dipan Mehta
Dipan Mehta of Elixir Equities discussed the outlook for the auto and cement industries, noting potential slowdowns and increased competition. He commented on recent developments in speculative trading regulations, the pharma sector, and the performance of companies like Zomato, Paytm, and Maruti. Mehta advised caution in the auto sector while expressing optimism about select pharma stocks.
Mankind Pharma Q1 Results: Net profit jumps 10% to Rs 543 crore
The drug maker reported net profit of Rs 494 crore in the corresponding period of previous year.Revenue from operations rose 12.2% YoY to Rs 2,893 crore in Q1FY25. On a quarter-on-quarter (QoQ) basis revenue and net profit increased 18.5% and 14%, respectively.
Mankind Pharma Q1 Results: Profit rises 10% YoY to Rs 543 crore
Mankind Pharma Q1 Results: Revenue from operations for the same period increased by 12% year-on-year (YoY) to Rs 2,893 crore, up from Rs 2,579 crore in the previous year. The company reported an EBITDA of Rs 681 crore, reflecting a 4% YoY increase. However, margins for the quarter declined by 188 basis points to 23.54%.
Q1 results today: Maruti, M&M among 115 companies to announce earnings on Wednesday
Q1 results today: In the first quarter earnings season, 115 companies announced results, including Maruti, M&M, Coal India, Adani Power, Tata Steel, Ambuja, and Bank of Baroda. M&M and Maruti expected mixed revenue and profit changes, while Tata Steel's profit was predicted to rise notably amid a revenue drop. Several others also reported their quarterly performance.
Q1 results today: Tata Consumer, Varun Beverages among 91 companies to announce earnings on Tuesday
Q1 Results Today: As first quarter earnings season progressed, 91 companies, like IOC and Tata Consumer, disclosed results. Tata Consumer is expected to exhibit 13% revenue growth due to strong India foods business. However, profit estimates vary. The company's EBITDA margin for the first quarter is projected to rise to 15.3% due to better gross margins.
Q1 results this week: ITC, SBI, TaMo, Zomato among 130 firms to announce earnings
This week, several prominent companies released their June quarter financial results. Firms like ITC, SBI, Adani Ports, Tata Motors, and M&M showcased their reports between July 29th and August 3rd. The updates offered a glimpse into their quarterly performance, engaging the attention of investors and stakeholders.
Piramal Pharma Q1 Results: Net loss narrows to Rs 89 crore
Piramal Pharma Q1 Earnings: Piramal Pharma narrowed its net loss to Rs 89 crore in Q1FY25 from a net loss of Rs 99 crore in the corresponding quarter of the previous year.
Cipla Q1 Results: Cons PAT rises 18% YoY to Rs 1,178 crore, beats estimates
Cipla Q1 Results: The profit beat the ET Now Poll estimates of Rs 1,071 crore. Revenue from operations in the reporting period increased 6% year-on-year to Rs 6,694 crore. EBITDA saw a 14% year-on-year increase, reaching Rs 1,716 crore. This growth was primarily driven by the One India business' branded prescription division, which experienced a 10% growth. This growth was particularly strong in focused chronic therapies like respiratory, cardiac, and urology, outpacing the market. The overall chronic mix in the portfolio also improved by 106 basis points year-on-year, reaching 61.5%.
Q1 results today: IndiGo, IndusInd among 69 companies to announce earnings on Friday
Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, ESAF SFB, Equitas SFB, Mangalam Organics, Piramal Pharma, TTK Prestige among others will also declare their results.
J&J Q2 Results: Pharma major beats Wall Street estimates on strong drug sales
Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.
Budget 2024: More funds and focus on R&D can solve many problems of pharma sector, say stakeholders
The upcoming budget should focus on streamlining regulatory compliance and help the domestic pharma sector to boost their manufacturing capacity.
TCS, Infy power D-Street to fresh record highs! Sensex soars 900 points, Nifty tops 24,500 for the first time
Indian markets rose Friday, led by TCS's strong June quarter. Sensex climbed 281 points, Nifty50 up 93 points. Stocks like TCS, Infosys, and Adani Ports surged. Maruti fell. US inflation data raised September Fed rate cut chances, noted by CME FedWatch. RBI's Das predicted 5% retail inflation. Powell's testimony hinted at possible rate cuts.
Ajanta Pharma buyback: Last day today to buy shares for Rs 285 crore special situation opportunity
Ajanta Pharma has set May 30 as the record date for its Rs 285 crore share buyback,. The buyback, at a premium of 12.6%, targets 10,28,881 equity shares, constituting 8.34% of the company's aggregate equity. Amidst strong financials, the company reported a 66% YoY growth in PAT and a 20% YoY increase in revenue in its Q4 results.
Torrent Pharma, Glenmark Pharma shares jump up to 9% after Q4 results
Shares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma reported increased losses. Motilal Oswal provides target prices for both companies.
Q4 results today: LIC, NMDC among 236 companies to announce earnings on Monday
236 companies, including LIC and NMDC, to announce Q4 results. LIC reported a 49% rise in Q3 earnings, while NMDC saw a 62% increase in consolidated net profit.
Torrent Pharma board approves to raise Rs 5,000 crore
Torrent Pharmaceuticals, actively seeking to expand through acquisitions, has expressed interest in purchasing Mumbai-based pharmaceutical company JB Pharma, according to a report by ET on Friday.
Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY
Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.
Sun Pharma net profit jumps 34% YoY to Rs 2,654.6 crore in Q4FY24
Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.
Strides Pharma Q4 Results: Pharma co reports Rs 10.4 crore net profit
Strides Pharma Science posted a net profit of Rs 10.4 crore in Q4FY24, rebounding from a loss of Rs 1 crore in the same period last year. Pre-tax profit was Rs 29.6 crore.
Sun Pharma Q4 Results: Profit jumps 34% YoY to Rs 2,654 crore, meets Street estimates
Sun Pharma Q4 Results: The company's revenue rose 10% year-on-year to Rs 11,983 crore in the reporting quarter. It was Rs 10,931 crore a year ago. Its board has approved a final dividend of Rs 5 per share, which will be paid within the prescribed timeline. India formulations sales were Rs 3,707 crore for the fourth quarter, showing growth of 10% over Q4 last year and accounted for 31.4% of total consolidated sales for the quarter.
Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 crore
Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.
Load More
